FDA Expands Indication for Dako's PD-L1 'Complementary' Diagnostic | GenomeWeb

NEW YORK (GenomeWeb) – The US Food and Drug Administration has expanded the intended use for Dako's PD-L1 IHC 28-8 pharmDx as a complementary diagnostic to assess the magnitude of benefit melanoma patients might derive from the immunotherapeutic Opdivo (nivolumab), the Agilent subsidiary announced today.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.

A cancer researcher retracts 19 articles from one journal for image manipulation, according to Retraction Watch.

Precision medicine has to consider context in addition to genetic mutations in cancer treatment, Medscape reports.

Genomics may help the Cavendish banana from succumbing to fungal infections, a trio of researchers writes at the Conversation.

Sponsored by
Agilent Technologies

In this online seminar, speakers from the Center for Personalized Diagnostics at Penn Medicine will discuss the design and technical validation of a custom next-generation sequencing panel to detect mutations in a wide array of tumor types.